 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123 |
- | 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead, 3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
Trial completion, Trial completion date, Trial primary completion date: 3BNC117 and 10-1074 in HIV Uninfected Adults (clinicaltrials.gov) - Apr 17, 2018
P1, N=24, Completed, Sponsor: Rockefeller University
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018
- | 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
Trial completion: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Feb 5, 2018
P1, N=33, Completed, Sponsor: Rockefeller University
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018 Active, not recruiting --> Completed
- | 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
Trial primary completion date: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Aug 8, 2017
P1, N=33, Active, not recruiting, Sponsor: Rockefeller University
Active, not recruiting --> Completed Trial primary completion date: Jul 2017 --> Dec 2016
- | 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead, 3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
Enrollment closed: 3BNC117 and 10-1074 in HIV Uninfected Adults (clinicaltrials.gov) - Apr 5, 2017
P1, N=24, Active, not recruiting, Sponsor: Rockefeller University
Trial primary completion date: Jul 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
Enrollment change: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Dec 28, 2016
P1, N=33, Active, not recruiting, Sponsor: Rockefeller University
Recruiting --> Active, not recruiting N=51 --> 33
- 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
Enrollment closed: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Sep 14, 2016
P1, N=51, Active, not recruiting, Sponsor: Rockefeller University
N=51 --> 33 Recruiting --> Active, not recruiting
- 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead, 3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
New P1 trial: 3BNC117 and 10-1074 in HIV-infected Individuals (clinicaltrials.gov) - Jul 7, 2016
P1b, N=37, Recruiting, Sponsor: Rockefeller University
- 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead, 3BNC117 / Rockefeller University, Cornell University, Frontier Biotech, Gilead
New P1 trial: 3BNC117 and 10-1074 in HIV Uninfected Adults (clinicaltrials.gov) - Jul 6, 2016
P1, N=24, Recruiting, Sponsor: Rockefeller University
- 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
Trial primary completion date: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Apr 27, 2016
P1, N=51, Recruiting, Sponsor: Rockefeller University
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2016 --> Jul 2017
- ||| 10-1074 / National Institute of Allergy and Infectious Diseases, Rockefeller University, Gilead
New P1 trial: A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 (clinicaltrials.gov) - Jul 30, 2015
P1, N=51, Recruiting, Sponsor: Rockefeller University